title: Antitumor and immunomodulatory effects of salvigenin on tumor bearing mice.
abstract: Development of agents that specifically kill cancer cells and simultaneously elicit antitumor immune response is a step forward in cancer therapy. Immunostimulation can result in eliminating of the cancer cells; immunotherapy is a promising approach in balancing the immune response by Treg. In the present study, we investigated whether the administration of salvigenin contributes to the augmentation of antitumor immunity and the regression of tumor tissues in a mouse model of breast cancer. Salvigenin was purified from Tanacetum canescens, and its effect on the tumor volume was investigated. The splenocyte proliferation, shifting of cytokine profile, and the presence of naturally-occurring CD4+CD25+Foxp3+ Treg cells were assessed to describe the anti-tumor immune response. Our results demonstrated that a significant decrease in the level of IL-4 and increase in the IFN-γ in the animals treated with salvigenin and significant decreased in the level of splenic CD4+CD25+Foxp3+ T regulatory cells. The cytotoxic and immunomodulatory properties of salvigenin were acknowledged in vivo.
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: shnoori@sbmu.ac.ir.
authors.forename: Shokoofe
authors.initials: S
authors.lastname: Noori
authors.affiliation: Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Zuhair M
authors.initials: ZM
authors.lastname: Hassan
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Bahram
authors.initials: B
authors.lastname: Yaghmaei
authors.affiliation: International Branch of Shahid Beheshti University of Medical Sciences, Tehran, Iran.
authors.forename: Milad
authors.initials: M
authors.lastname: Dolatkhah
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000302:isolation & purification / Q000494:pharmacology*; D015704:CD4 Antigens / Q000235:genetics / Q000276:immunology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D049109:Cell Proliferation; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D047309:Flavones / Q000302:isolation & purification / Q000494:pharmacology*; D051858:Forkhead Transcription Factors / Q000235:genetics / Q000276:immunology; D015870:Gene Expression; D007155:Immunologic Factors / Q000302:isolation & purification / Q000494:pharmacology*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D053645:Interleukin-2 Receptor alpha Subunit / Q000235:genetics / Q000276:immunology; D015847:Interleukin-4 / Q000096:biosynthesis / Q000276:immunology; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D051379:Mice; D013154:Spleen / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D031203:Tanacetum / Q000737:chemistry; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D015704:CD4 Antigens; D047309:Flavones; D051858:Forkhead Transcription Factors; C498833:Foxp3 protein, mouse; D007155:Immunologic Factors; D053645:Interleukin-2 Receptor alpha Subunit; C014049:salvigenin; D015847:Interleukin-4; D007371:Interferon-gamma
keywords: IFN-γ; IL-4; Immunomodulator; Regulatory T cells; Salvigenin